Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305457 · ClinicalTrials.gov registry record · Phase 2
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04305457: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04305457 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04305457, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on SARS-CoV-2 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
Interventions
- DRUG Nitric Oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-03-21 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305457
The ClinicalTrials.gov registry entry for NCT04305457 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nitric Oxide is the first listed.
NCT04305457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04305457 about?
NCT04305457 is a clinical study titled "Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19". The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia s...
What is the current status of trial NCT04305457?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2020-03-21. Estimated completion is 2023-08-23.
What interventions are being tested in trial NCT04305457?
The interventions under investigation include: Nitric Oxide (DRUG).
Who is sponsoring clinical trial NCT04305457?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.